Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
NMD Pharma A/S · NCT06414954
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 84
- US sites recruiting
- 9
- Study start
- May 16, 2024
- Record last updated
- August 21, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.
Being studied: NMD670; Placebo
Conditions: Myasthenia Gravis; Myasthenia Gravis, MuSK
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Participant must be a male or female being 18 or more, at the time of signing the informed consent
- Diagnosis of MG, MGFA class II, III or IV
- Documented positive AChR or MuSK antibody test.
- Participant must be able to swallow tablets
- Body mass index between 18 and 35 kg/m2, inclusive, at screening, and with a minimum weight of 40 kg
- Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- Participant is capable of and has given signed informed consent
Exclusion Criteria
- Known medical or psychological condition(s) or risk factor that, in the opinion of the Investigator, might interfere with the patient's full participation in the study, pose any additional risk for the patient, or confound the assessment of the patient or outcome of the study
- Participants with other significant clinical and/or laboratory safety findings that may interfere with the conduction or interpretation of the study
- Participants that received treatment with an investigational medical product within 30 days or 5 half-lives of the medication, whichever is longer prior to Day 1
- Participants with history of poor compliance with relevant MG therapy
- Female patients who plan to become pregnant during the study or are currently pregnant or breastfeeding
Recruiting US locations
University of California Irvine Medical Center
Irvine, CA 92868
Site contact: Siddhant Partap · 650-224-2637 · spratap1@hs.uci.edu
University of Colorado Neuromuscular Division
Aurora, CO 80045
Site contact: Alexis Shepardson · 303-724-4644 · neuroresearch@cuanschutz.edu
SFM Clinical Research, LLC
Boca Raton, FL 33487
Site contact: Gabrielle DeMaria · (561) 939-0333
Neuromuscular Research Division | University of South Florida
Tampa, FL 33612
Site contact: Jessica Shaw · 813-974-9413 · jessshaw@usf.edu
Augusta University, Neuroscience Center
Augusta, GA 30912
Site contact: Brandy Quarles · 706-721-0390 · neuromuscular_research@augusta.edu
NextGen Precision Health
Columbia, MO 65212
Site contact: Neetha Gali · (573) 882-3065 · ngdcd@health.missouri.edu
The University of North Carolina at Chapel Hill
Chapel Hill, NC 27599
Site contact: Manisha Chopra · 1-919-843-7857 · chopram@neurology.unc.edu
The Ohio State University
Columbus, OH 43221
Site contact: Lischele Watkins,, MACPR · 614-293-1737 · Lischele.Watkins@osumc.edu
University of Oregon
Portland, OR 97239
Site contact: Katie Lewis · 503-494-5236 · lewiskat@ohsu.edu
Study contacts (from the official record)
- NMD Pharma A/S · contact@nmdpharma.com · contact@nmdpharma.com